8 results
424B5
FENC
Fennec Pharmaceuticals Inc
1 May 20
Prospectus supplement for primary offering
5:28pm
to increase the pressure on drug pricing. If third-party payors do not consider our products to be cost-effective compared to other available therapies … products at a profit.
Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time, and there is the potential
424B5
yd9j1jw5zp 9v
29 Apr 20
Prospectus supplement for primary offering
4:48pm
- Prev
- 1
- Next